Blind gamer Ben Breen wants more studios to consider people like him when developing videogames.
BBC Scotland news website
But now he wants to see all big gaming studios consider people with sight loss when developing games. "I still do play audio-only games occasionally," Ben said. "But I prefer stuff when it's enjoyable for more people."Screen narration tells the user what is happening visually on the screen, while navigation assistance tools allow the player to determine their distance from objects and enemies.
He said: "As much as we've had games released on a couple of platforms that are fully playable, we need to see all the companies stepping up.Ben added: "Sight loss is a spectrum and gaming can still happen, but more needs to be done in terms of making games accessible.He said studios need to accept that accessibility is important and he wants to see people with sight loss consulted during the development of games.
"Beyond that, you get much more challenging things like making decisions around something that's happening that's really visual."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ben & Jerry’s vs Unilever: how a star acquisition became a legal nightmare\n\t\t\tKeep abreast of significant corporate, financial and political developments around the world.\n\t\t\tStay informed and spot emerging risks and opportunities with independent global reporting, expert\n\t\t\tcommentary and analysis you can trust.\n\t\t
Read more »
Retired Hamilton man reflects on sight-saving surgery and 40 years volunteeringIain Neilson almost went blind when he was diagnosed with a rare eye disease which caused swelling and inflammation in the coloured ring around the pupil, however, major surgery saved his sight.
Read more »
Bosses at energy firms owned by football boss Andy Pilley 'at best, turned blind eye' to fraudulent mis-sellingFraudulent mis-selling of energy supply contracts by companies owned by football boss Andy Pilley was rife, a court heard today (October 12).
Read more »
Three economists win the Nobel for their work on bank runsResearch by Ben Bernanke, Douglas Diamond and Philip Dybvig was largely vindicated by the failure of the banks in 2008
Read more »
Bank wrongly tells couple they're both dead leaving 'mental health in tatters'Ben Gibson and his wife Gill's nightmare began when they contacted the bank for replacement cards after theirs stopped working, only to be informed they were both dead.
Read more »
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate - The Journal of Prevention of Alzheimer's DiseaseBackground Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog11) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL23). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.
Read more »